@article {2389,
	title = {Cytotoxicity of the traditional chinese medicine (TCM) plumbagin in its copper chemistry},
	journal = {Dalton Transactions},
	number = {48},
	year = {2009},
	note = {ISI Document Delivery No.: 527IETimes Cited: 3Cited Reference Count: 96Chen, Zhen-Feng Tan, Ming-Xiong Liu, Li-Min Liu, Yan-Cheng Wang, Heng-Shan Yang, Bin Peng, Yan Liu, Hua-Gang Liang, Hong Orvig, Chris},
	pages = {10824-10833},
	type = {Article},
	abstract = {The anticancer traditional Chinese medicine (TCM), plumbagin (PLN), was isolated from Plumbago Zeylanica. Reaction of plumbagin with Cu-II salt, afforded [Cu(PLN)(2)]center dot 2H(2)O (1). With 2,2{\textquoteright}-bipyridine (bipy) as a co-ligand, PLN reacts with Cu-II to give [Cu(PLN)(bipy)(H2O)](2)(NO3)(2)center dot 4H(2)O (2). 1 and 2 were characterized by elemental analysis, IR, ESI-MS spectra. Their crystal structures were determined by single crystal X-ray diffraction methods. The in vitro cytotoxicity of PLN, 1 and 2 against seven human tumour cell lines was assayed. The metal-based compounds exhibit enhanced cytotoxicity vs. that of free PLN, suggesting that these compounds display synergy in the combination of metal ions with PLN. The binding properties of PLN, 1 and 2 to DNA were investigated through UV-vis, fluorescence, CD spectra, and gel mobility shift assay, which indicated that 1 and 2 were non-covalent binding and mainly intercalated the neighboring base pairs of DNA. PLN, 1 and 2 exhibit inhibition activity to topoisomerase I (TOPO I), but 1 and 2 were more effective than PLN.},
	keywords = {BIOLOGICAL-ACTIVITY, CALF-THYMUS DNA, CANCER-CELLS, CRYSTAL-STRUCTURE, DNA CLEAVAGE ACTIVITY, IRON(II) COMPLEXES, METAL-COMPLEXES, N-PROPYL-NORFLOXACIN, PLATINUM ANTICANCER AGENTS, TOPOISOMERASE-I},
	isbn = {1477-9226},
	url = {<Go to ISI>://000272359900024},
	author = {Chen, Z. F. and Tan, M. X. and Liu, L. M. and Liu, Y. C. and Wang, H. S. and Yang, B. and Peng, Y. and Liu, H. G. and Liang, H. and Orvig, Chris}
}
@article {2437,
	title = {Identification of Nitroxyl-induced Modifications in Human Platelet Proteins Using a Novel Mass Spectrometric Detection Method},
	journal = {Molecular \& Cellular Proteomics},
	volume = {8},
	number = {5},
	year = {2009},
	note = {ISI Document Delivery No.: 446JCTimes Cited: 5Cited Reference Count: 67Hoffman, Michael D. Walsh, Geraldine M. Rogalski, Jason C. Kast, Juergen},
	month = {May},
	pages = {887-903},
	type = {Article},
	abstract = {Nitroxyl (HNO) exhibits many important pharmacological effects, including inhibition of platelet aggregation, and the HNO donor Angeli{\textquoteright}s salt has been proposed as a potential therapeutic agent in the treatment of many diseases including heart failure and alcoholism. Despite this, little is known about the mechanism of action of HNO, and its effects are rarely linked to specific protein targets of HNO or to the actual chemical changes that proteins undergo when in contact with HNO. Here we study the presumed major molecular target of HNO within the body: protein thiols. Cysteine-containing tryptic peptides were reacted with HNO, generating the sulfinamide modification and, to a lesser extent, disulfide linkages with no other long lived intermediates or side products. The sulfinamide modification was subjected to a comprehensive tandem mass spectrometric analysis including MS/MS by CID and electron capture dissociation as well as an MS3 analysis. These studies revealed a characteristic neutral loss of HS(O)NH2 (65 Da) that is liberated from the modified cysteine upon CID and can be monitored by mass spectrometry. Upon storage, partial conversion of the sulfinamide to sulfinic acid was observed, leading to coinciding neutral losses of 65 and 66 Da (HS(O)OH). Validation of the method was conducted using a targeted study of nitroxylated glyceraldehyde-3-phosphate dehydrogenase extracted from Angeli{\textquoteright}s salt-treated human platelets. In these ex vivo experiments, the sample preparation process resulted in complete conversion of sulfinamide to sulfinic acid, making this the sole subject of further ex vivo studies. A global proteomics analysis to discover platelet proteins that carry nitroxyl-induced modifications and a mass spectrometric HNO dose-response analysis of the modified proteins were conducted to gain insight into the specificity and selectivity of this modification. These methods identified 10 proteins that are modified dose dependently in response to HNO, whose functions range from metabolism and cytoskeletal rearrangement to signal transduction, providing for the first time a possible mechanistic link between HNO-induced modification and the physiological effects of HNO donors in platelets. Molecular \& Cellular Proteomics 8: 887-903, 2009.},
	keywords = {ACTIVATION, ALDEHYDE, ALZHEIMERS-DISEASE, BIOLOGICAL-ACTIVITY, DEHYDROGENASE, DETERRENT AGENT CYANAMIDE, INTEGRIN, NITRIC-OXIDE, NITROGEN-OXIDE, NMDA RECEPTOR, S-NITROSYLATION, SUCCINIMIDE FORMATION},
	isbn = {1535-9476},
	url = {<Go to ISI>://000266116900002},
	author = {Hoffman, M. D. and Walsh, G. M. and Rogalski, J. C. and Kast, J.}
}
@article {1015,
	title = {Triggering DNAzymes with light: A photoactive C8 thioether-linked adenosine},
	journal = {Journal of the American Chemical Society},
	volume = {126},
	number = {40},
	year = {2004},
	note = {ISI Document Delivery No.: 860QITimes Cited: 31Cited Reference Count: 36},
	month = {Oct},
	pages = {12720-12721},
	type = {Article},
	keywords = {BIOLOGICAL-ACTIVITY, DEOXYRIBOZYME, DNA, ENZYME, MESSENGER-RNA, NUCLEOSIDE, PROTEINS, PURINES},
	isbn = {0002-7863},
	url = {<Go to ISI>://000224357700005},
	author = {Ting, R. and Lermer, L. and Perrin,David M.}
}
@article {742,
	title = {Vanadyl-thiazolidinedione combination agents for diabetes therapy},
	journal = {Bioconjugate Chemistry},
	volume = {14},
	number = {1},
	year = {2003},
	note = {ISI Document Delivery No.: 637YYTimes Cited: 23Cited Reference Count: 42},
	month = {Jan-Feb},
	pages = {212-221},
	type = {Article},
	abstract = {A series of vanadium compounds, chelated by ligands containing a thiazolidinedione moiety as an additional insulin-enhancing component, were produced in this study to create potentially synergistic compounds. A set of four bifunctional ligand precursors were synthesized: (+/-)-5-4-[(5-hydroxy-4-oxo-4H-pyran-2-ylmethyl)amino]benzylthiazolidi ne-2,4-dione (HL1), (+/-)-5-4-[5-hydroxy-1-methyl-4-oxo-1,4-dihydro-pyridin-2-ylmethyl)amin o]benzylthiazolidine-2,4-dione (HL2) 5-[4-(5-hydroxy-4-oxo-4H-pyran-2-ylmethoxy)benzylidenelthiazolidine-2,4- dione (HL1), and (+/-)-5-4-(5-hydroxy-4-oxo-4H-pyran-2-ylmethoxy)benzyl]thiazolidine-2,4 -dione (HL4), each containing a metal chelating portion as well as a thiazolidinedione moiety. From this set of ligand precursors, air-stable VO(L-1)(2), VO(L-3)(2), and VO(L-4)(2) were prepared. The four ligand precursors and three complexes were tested for insulin-enhancing potential in STZ-diabetic rats and compared to rosiglitazone and BMOV, respectively. Both the ligand precursors HL1 and HL3 showed enhanced activity compared with that of rosiglitazone. The complex VO(L-3)(2) showed the most efficacious hypoglycemic effects in this study; however, neither additive nor synergistic effects were observed using this acute animal model.},
	keywords = {AGENT, ANTIHYPERGLYCEMIC, BIOLOGICAL-ACTIVITY, BIS(MALTOLATO)OXOVANADIUM(IV), BLOOD-GLUCOSE, COMPLEXES, DERIVATIVES, GLUCOSE-LOWERING PROPERTIES, INSULIN MIMETIC AGENT, RAT ADIPOCYTES, TROGLITAZONE},
	isbn = {1043-1802},
	url = {<Go to ISI>://000180542400025},
	author = {Storr, T. and Mitchell, D. and Buglyo, P. and Thompson, K. H. and Yuen, V. G. and McNeill, J. H. and Orvig, Chris}
}
@article {5209,
	title = {Coordination chemistry of vanadium in metallopharmaceutical candidate compounds},
	journal = {Coordination Chemistry Reviews},
	volume = {219},
	year = {2001},
	note = {ISI Document Delivery No.: 478JQTimes Cited: 138Cited Reference Count: 119},
	month = {Sep-Oct},
	pages = {1033-1053},
	type = {Review},
	abstract = {The discovery of vanadium{\textquoteright}s insulin-like behaviour in vitro, and later of the orally available glucose- and lipid-lowering capability of these same compounds in vivo, has stimulated renewed interest in vanadium coordination chemistry. Besides the anti-diabetic effects for which it is now so well known, vanadium also exhibits a number of other therapeutic effects including anti-tumour and anti-inflammatory activities. In this review, emphasis will be on the most recent developments in the coordination chemistry of vanadium(III), (IV) and (V), as related to development of these compounds for pharmaceutical use. How best to measure bioactivity and the pharmaceutical relevance of accompanying increased oxidative stress will also be considered. (C) 2001 Elsevier Science B.V. All rights reserved.},
	keywords = {bioactivity, BIOLOGICAL-ACTIVITY, CANCER, CRYSTAL-STRUCTURE, Diabetes mellitus, DIABETES-MELLITUS, ESEEM, INSULIN-LIKE ACTIVITIES, OXIDATIVE STRESS, OXOVANADIUM(IV) COMPLEXES, OXYGEN-BRIDGED DIMER, PEROXO HETEROLIGAND VANADATES(V), pharmaceutical agents, RAY, SPECTROSCOPIC PROPERTIES, structure-activity relationships, TYROSINE PHOSPHORYLATION, vanadium complexes},
	isbn = {0010-8545},
	url = {<Go to ISI>://000171343600035},
	author = {Thompson, K. H. and Orvig, Chris}
}
